A formal appeal has been lodged with the NHS spending watchdog following its decision to withdraw a potentially life-saving cancer treatment from health services across England and Wales.
Tecartus, a pioneering therapy that re-engineers a patient’s own immune cells to target and destroy cancer, was initially made available for individuals suffering from a rare form of non-Hodgkin lymphoma.
